גפטיניב ס.ק. - Gefitinib s.k

× ×ª×× × ×ª×¨××¤×

×××¨×©×

×§×××¦× ×¤×¨××§××××××ª (ATC4)	L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
××¨××× ×¤×¢×× (ATC5)	Â Gefitinib 250 MG âL01EB01
×¦××¨×ª ××ª×	×¤××× - PER OS
×¦××¨×ª ××× ××	××××××ª ××¦××¤××ª ×¤×××, FILM COATED TABLETS ××× ××¢×ª ××× ×× ××ª×¨ ×× ××¨×¢×× ××© ××××× ××ª ××ª×¨××¤× ×××ª×× ×××× ×× ××××××¥ ××¤× ×©×××¤××¢ ××¢××× ××¦×¨××
××ª××××	Gefitinib S.K. is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK
×¢××× ××¨××¤× ×××××¨××ª ××¢×××	××× ×¢××× ××¨××¤× Â

×¢××× ××¦×¨××	Â

×¢×¨××× ×××××§××¨×¤×××	×¢×¨××× ×§×©××¨×× ×××××§××¨×¤×××
××¤××× ×× ×¡.×§. ×××××¨ ××©×¨× ×××¨××××ª

×××¤××© ××××¨××	××××¨×× ×-PubMed
××××¢ ××¨×©×ª	RxList WebMD Drugs.com
×©× ××¦×¨×	SYNTHON B.V., NETHERLANDS
×©× ××¢× ××¨××©××	K.S.KIM INTERNATIONAL (SK- PHARMA) LTD., ISRAEL
×¨××©×××	×ª××¨×× ×××©×: 9/2019. ×¨××©××× ××ª××¨××:
×ª××¨×× ×¢×××× ×××¨××	09/07/2024

השינוי האחרון נעשה בֹ־9 ביולי 2024 ב־13:12